leadf
logo-loader
viewBiocept Inc
(
NASDAQ:BIOC
)

Biocept says its lab received to-date more than 350,000 coronavirus testing samples for processing

These samples are processed using Biocept’s RT-PCR technology at its CLIA-certified, CAP-accredited high-complexity molecular laboratory in San Diego

Biocept Inc - Biocept Inc says its San Diego lab received to-date more than 350,000 coronavirus testing samples for processing
The company is moving ahead with plans to improve testing as a way to identify new variants of the SARS-CoV-2 virus which causes the COVID-19 disease

Biocept Inc (NASDAQ:BIOC) (FRA:B003) reports that since the company began offering SARS-CoV-2 testing services in June 2020, it has now received more than 350,000 samples.  

These test samples are processed using Biocept’s RT-PCR technology at its CLIA-certified, CAP-accredited high-complexity molecular laboratory in San Diego. 

“We are exceptionally proud to continue supporting our community with SARS-CoV-2 testing and providing healthcare providers with rapid turnaround of valuable information to help contain viral spread,” said Michael Nall, president and CEO of Biocept.  

READ: Biocept posts first-ever quarterly profit and balloons 4Q revenue to $18.5M on strength of coronavirus testing

“RT-PCR testing for COVID-19 currently remains an important component of our business while we focus on our core business, including the opportunity to serve patients diagnosed with advanced cancer through commercializing our differentiated CNSide neuro-oncology offerings,” Nall added.

To further strengthen its COVID-19 testing business, the company is moving ahead with plans to improve testing as a way to identify new variants of the SARS-CoV-2 virus, which causes the disease. 

Biocept recently partnered with Aegea Biotechnologies Inc under a supply agreement for a new PCR-based coronavirus assay kit designed by Aegea and co-developed by both companies. 

Aegea will supply the kit to Biocept for validation in its San Diego lab and the new assay will use Biocept’s patent-protected Switch-Blocker technology for viral RNA detection and discrimination of the L and S coronavirus strain types. 

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

Quick facts: Biocept Inc

Follow
NASDAQ:BIOC

Price: 4.07 USD

Market Cap: $59.92 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Biocept approved for expanded Medicare coverage for its Target Selector...

Biocept Inc (NASDAQ:BIOC) (NASDAQ:BIOC) (FRA:B003) CEO Mike Nall tells Proactive it has received a positive final Local Coverage Determination from the Centers for Medicare & Medicaid Services Molecular Diagnostics Program, which will expand Medicare coverage for use of Biocept’s Target...

on 07/27/2021

2 min read